$1.14/ day, billed weekly
Cancel anytime

(Ad-Free, Unlimited access)

NO CREDIT CARD REQUIRED

APDN

Applied DNA Sciences Inc (APDN)

$1.93

Delayed price

PASS

BUY Advisory
SELL Advisory (Profit)
SELL Advisory (Loss)

Profit
Loss
Pass (Skip investing)

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

03/20/2025: APDN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock

Historic Profit -86.1%

Avg. Invested days 32

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

2.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 03/20/2025

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 2.13M USD	Price to earnings Ratio -	1Y Target Price 1.5
Price to earnings Ratio -	1Y Target Price 1.5
Volume (30-day avg) 959581	Beta 0.42	52 Weeks Range 1.67 - 499.90	Updated Date 03/20/2025
52 Weeks Range 1.67 - 499.90	Updated Date 03/20/2025
Dividends yield (FY) -	Basic EPS (TTM) -32.5

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -228.18%

Operating Margin (TTM) -247.7%

Management Effectiveness

Return on Assets (TTM) -63.75%

Return on Equity (TTM) -103.45%

Valuation

Trailing PE -	Forward PE -	Enterprise Value -6556802	Price to Sales(TTM) 0.57
Enterprise Value -6556802	Price to Sales(TTM) 0.57
Enterprise Value to Revenue 0.88	Enterprise Value to EBITDA -0.34	Shares Outstanding 1103770	Shares Floating 959971
Shares Outstanding 1103770	Shares Floating 959971
Percent Insiders 19.47	Percent Institutions 26.9

Analyst Ratings

Rating 3	Target Price 1.5	Buy -	Strong Buy -
Buy -	Strong Buy -
Hold 1	Sell -	Strong Sell -
Strong Sell -

Upturn AI SWOT

Applied DNA Sciences Inc. (APDN) - Comprehensive Overview

Company Profile:

History and Background:

Founded in 1987, Applied DNA Sciences (APDN) is a leading biotechnology company pioneering molecular-based technologies.
Began with developing oligonucleotide synthesis for diagnostics and research, later expanded into anti-counterfeiting and security solutions.
Acquired LineaRx, a leader in DNA-based personalized medicine, in 2011.

Core Business Areas:

Security & Anti-Counterfeiting:
- Signature® DNA markers used for product authentication, traceability, and anti-counterfeiting.
- Diverse applications across industries: Pharmaceuticals, apparel, food & beverage, and luxury goods.
Precision Medicine:
- Personalized medicine platform based on DNA analysis.
- Identifies genetic markers associated with disease risk and drug response.
- Focus on cancer, cardiovascular disease, and infectious diseases.
Other Technologies:
- Molecular tagging for agriculture, biodefense, and industrial applications.
- DNA-based data storage solutions for long-term, secure data archiving.

Leadership & Structure:

Leadership: James A. Hayward (President & CEO), Mark S. Edwards (CFO & COO),
Corporate Structure: Board of Directors (6 members), Executive Management Team, and various scientific & operational departments.

Top Products and Market Share:

Top Products:

SigNature® DNA: Molecular tag used for anti-counterfeiting and authentication in various industries.
LineaRx™: Personalized medicine platform for genetic testing and diagnosis.
PreventID™: DNA-based tagging system for industrial and biodefense applications.

Market Share:

Security & Anti-Counterfeiting:
- Global market share difficult to estimate due to fragmentation.
- Significant presence in pharmaceutical and luxury goods industries.
Precision Medicine:
- Niche market with strong growth potential.
- LineaRx™ competes with established players like 23andMe and AncestryDNA.

Total Addressable Market:

Global market for anti-counterfeiting technologies estimated at $60 billion.
Precision medicine market expected to reach $112 billion by 2027.

Financial Performance:

Recent Financials:

Revenue (2022): $3.0 million (decline from 2021)
Net Income (2022): -$18.6 million (loss)
EPS (2022): -$0.41
Significant losses due to development costs and low product adoption.

Cash Flow and Balance Sheet:

Cash & Equivalents (2022): $7.7 million
High cash burn rate due to ongoing operations and R&D investment.
Debt-free.

Dividends and Shareholder Returns:

No dividend history (growth-focused company).
Shareholder returns negative in recent years due to declining stock price.

Growth Trajectory:

Historical growth hampered by slow product adoption and competition.
Future growth potential tied to commercialization of SigNature® DNA and LineaRx™.
Recent product launches and partnerships indicate future growth possibilities.

Market Dynamics:

Anti-counterfeiting market: Growing demand driven by rising counterfeiting issues.
Precision medicine market: Strong growth potential fueled by technological advancements.
APDN well-positioned to capitalize on these trends with its unique technologies.

Competitors:

Security & Anti-Counterfeiting:
- SICPA, Avery Dennison, Authentix.
Precision Medicine:
- 23andMe, AncestryDNA, Illumina.
Comparative Advantages:
- Patented SigNature® DNA technology.
- Personalized medicine platform with unique offerings.

Potential Challenges and Opportunities:

Challenges:
- Commercializing products and achieving widespread adoption.
- Securing funding for ongoing operations and R&D.
- Competition from established players in both markets.
Opportunities:
- Expanding partnerships with key industry players.
- Entering new high-growth markets with SigNature® and LineaRx™.
- Leveraging technological advancements to strengthen competitive advantages.

Recent Acquisitions:

2023:
- mDS Dx (biomarker development company)
- GenePeeks (molecular diagnostics company)

2022:

No acquisitions reported.

AI-Based Fundamental Rating:

2/10
Justification: Weak financials, low market share, and dependence on future product success.

Sources:

Applied DNA Sciences Inc. investor website: https://www.adnas.com/
Yahoo Finance: https://finance.yahoo.com/quote/APDN/
Market Research Reports (MarketsandMarkets, Grand View Research)

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions.

About Applied DNA Sciences Inc

Exchange NASDAQ	Headquaters Stony Brook, NY, United States
IPO Launch date 2003-07-15	Chairman & CEO Dr. James A. Hayward Ph.D., Sc.D.
Sector Healthcare	Industry Diagnostics & Research	Full time employees 46	Website https://www.adnas.com
Full time employees 46	Website https://www.adnas.com

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.